Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Genetic haplotypes in VWA8, OSBPL6, and ADAMTS9-AS2 are associated with immune-related adverse effects in ICI-treated patients with cancer.
Journal: Journal for immunotherapy of cancer
Published: September 22, 2025
Erratum: Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.
Journal: JCO precision oncology
Published: May 22, 2025
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 03, 2025
Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.
Journal: JCO precision oncology
Published: December 03, 2024
Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer.
Journal: JTO clinical and research reports
Published: June 26, 2024
Differences in systemic immune parameters in individuals with lung cancer according to race.
Journal: bioRxiv : the preprint server for biology
Published: June 25, 2024
Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial.
Journal: Cancer treatment and research communications
Published: June 10, 2024
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Journal: Lancet (London, England)
Published: August 09, 2023
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis.
Journal: Journal for immunotherapy of cancer
Published: June 28, 2023
TATDN2 resolution of R-loops is required for survival of BRCA1-mutant cancer cells.
Journal: Nucleic acids research
Published: May 28, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Journal: The New England journal of medicine
Published: March 01, 2023
Last Updated: 09/26/2026